272 related articles for article (PubMed ID: 9595982)
21. [Study of associated clinical variables and phenomenology of hallucinations in Parkinson's].
Cubo E; González M; Aguilar A; Quintana S
Neurologia; 2006; 21(1):12-8. PubMed ID: 16525921
[TBL] [Abstract][Full Text] [Related]
22. Profiling the most elderly parkinson's disease patients: Does age or disease duration matter?
Virameteekul S; Phokaewvarangkul O; Bhidayasiri R
PLoS One; 2021; 16(12):e0261302. PubMed ID: 34937068
[TBL] [Abstract][Full Text] [Related]
23. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.
Martinu K; Degroot C; Madjar C; Strafella AP; Monchi O
Eur J Neurosci; 2012 Feb; 35(4):572-83. PubMed ID: 22304628
[TBL] [Abstract][Full Text] [Related]
24. Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease.
Mancini F; Tassorelli C; Martignoni E; Moglia A; Nappi G; Cristina S; Pacchetti C
Clin Neuropharmacol; 2004; 27(1):33-7. PubMed ID: 15090935
[TBL] [Abstract][Full Text] [Related]
25. Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia.
Frakey LL; Friedman JH
J Neuropsychiatry Clin Neurosci; 2017; 29(1):22-25. PubMed ID: 27829318
[TBL] [Abstract][Full Text] [Related]
26. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
27. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
[TBL] [Abstract][Full Text] [Related]
28. Effects of levodopa on motor sequence learning in Parkinson's disease.
Feigin A; Ghilardi MF; Carbon M; Edwards C; Fukuda M; Dhawan V; Margouleff C; Ghez C; Eidelberg D
Neurology; 2003 Jun; 60(11):1744-9. PubMed ID: 12796524
[TBL] [Abstract][Full Text] [Related]
29. Improvement in Language Function Correlates with Gait Improvement in Drug-naïve Parkinson's Disease Patients Taking Dopaminergic Medication.
Murakami H; Momma Y; Nohara T; Mori Y; Futamura A; Sugita T; Ishigaki S; Katoh H; Kezuka M; Ono K; Miller MW; Kawamura M
J Parkinsons Dis; 2016; 6(1):209-17. PubMed ID: 26889633
[TBL] [Abstract][Full Text] [Related]
30. Levodopa and the feedback process on set-shifting in Parkinson's disease.
Au WL; Zhou J; Palmes P; Sitoh YY; Tan LC; Rajapakse JC
Hum Brain Mapp; 2012 Jan; 33(1):27-39. PubMed ID: 21438075
[TBL] [Abstract][Full Text] [Related]
31. Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease.
Espay AJ; Foster ED; Coffey CS; Uribe L; Caspell-Garcia CJ; Weintraub D;
J Neurol Sci; 2019 Jul; 402():81-85. PubMed ID: 31125734
[TBL] [Abstract][Full Text] [Related]
32. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease.
Högl BE; Gómez-Arévalo G; García S; Scipioni O; Rubio M; Blanco M; Gershanik OS
Neurology; 1998 May; 50(5):1332-9. PubMed ID: 9595983
[TBL] [Abstract][Full Text] [Related]
33. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
[TBL] [Abstract][Full Text] [Related]
34. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease.
Funkiewiez A; Ardouin C; Krack P; Fraix V; Van Blercom N; Xie J; Moro E; Benabid AL; Pollak P
Mov Disord; 2003 May; 18(5):524-30. PubMed ID: 12722166
[TBL] [Abstract][Full Text] [Related]
35. Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test.
Fabbri M; Coelho M; Guedes LC; Chendo I; Sousa C; Rosa MM; Abreu D; Costa N; Godinho C; Antonini A; Ferreira JJ
Parkinsonism Relat Disord; 2017 Jun; 39():37-43. PubMed ID: 28389156
[TBL] [Abstract][Full Text] [Related]
36. Neural dynamics of short and medium-term motor control effects of levodopa therapy in Parkinson's disease.
Contreras-Vidal JL; Poluha P; Teulings HL; Stelmach GE
Artif Intell Med; 1998 May; 13(1-2):57-79. PubMed ID: 9654379
[TBL] [Abstract][Full Text] [Related]
37. Impact of Acute Dopamine Replacement on Cognitive Function in Parkinson's Disease.
Seemiller J; Morrow C; Hinkle JT; Perepezko K; Kamath V; Pontone GM; Mills KA
Mov Disord Clin Pract; 2024 May; 11(5):534-542. PubMed ID: 38470011
[TBL] [Abstract][Full Text] [Related]
38. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
[TBL] [Abstract][Full Text] [Related]
39. A registry-based, case-control investigation of Parkinson's disease with and without cognitive impairment.
Papapetropoulos S; Ellul J; Polychronopoulos P; Chroni E
Eur J Neurol; 2004 May; 11(5):347-51. PubMed ID: 15142230
[TBL] [Abstract][Full Text] [Related]
40. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.
Krack P; Batir A; Van Blercom N; Chabardes S; Fraix V; Ardouin C; Koudsie A; Limousin PD; Benazzouz A; LeBas JF; Benabid AL; Pollak P
N Engl J Med; 2003 Nov; 349(20):1925-34. PubMed ID: 14614167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
